byemo-shutterstock-com-handshake-
ByEmo / Shutterstock.com
19 January 2017Americas

Biogen to pay $1.25bn to Forward Pharma in licensing deal

Biogen and Forward Pharma, a Denmark-based company, have entered into a settlement and licensing agreement under which Biogen will pay Forward Pharma $1.25 billion.

The licensing agreement will give Biogen an irrevocable licence to all intellectual property owned by Forward Pharma.

Under the settlement, Biogen will also pay Forward Pharma royalties on net sales of Biogen products for the treatment of multiple sclerosis (MS) that are covered by a Forward Pharma patent.

Michel Vounatsos, CEO of Biogen, said: “We are very pleased to have reached this settlement with Forward Pharma. We believe this agreement will clarify and strengthen our intellectual property for Tecfidera (dimethyl fumarate), the leading oral therapy for multiple sclerosis.”

The settlement and agreement do not resolve an ongoing interference proceeding and litigation in the US and EU. The interference proceeding will decide which company was first to invent a treatment for MS with 480mg daily dose of DMF, the active ingredient in Tecfidera.

Biogen and Forward Pharma intend to permit the Patent Trial and Appeal Board, the US Court Appeals for the Federal Circuit, the European Patent Office, and the EPO’s Technical Board of Appeal and Enlarged Board of Appeal to make a final decision in the proceedings.

Florian Schonharting, chairman of Forward Pharma’s board of directors, said: “We are excited to enter into this agreement with Biogen and believe it is in the best interests of Forward shareholders.”

He added that the agreement limits Forward Pharma’s “downside risk” should it not be successful in either the US or European proceedings.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Americas
26 May 2017   Biogen has asked the US District Court for the Eastern District of California to dismiss a competition complaint filed by biotech company Ixchel Pharma.
Americas
7 September 2017   Forward Pharma has filed its opening brief in an appeal against a decision by the Patent Trial and Appeal Board (PTAB).
Big Pharma
6 February 2020   US multinational biotechnology company Biogen has successfully defended multiple sclerosis treatment Tecfidera from a patent challenge brought by generic and specialty pharma company Mylan.

More on this story

Americas
26 May 2017   Biogen has asked the US District Court for the Eastern District of California to dismiss a competition complaint filed by biotech company Ixchel Pharma.
Americas
7 September 2017   Forward Pharma has filed its opening brief in an appeal against a decision by the Patent Trial and Appeal Board (PTAB).
Big Pharma
6 February 2020   US multinational biotechnology company Biogen has successfully defended multiple sclerosis treatment Tecfidera from a patent challenge brought by generic and specialty pharma company Mylan.

More on this story

Americas
26 May 2017   Biogen has asked the US District Court for the Eastern District of California to dismiss a competition complaint filed by biotech company Ixchel Pharma.
Americas
7 September 2017   Forward Pharma has filed its opening brief in an appeal against a decision by the Patent Trial and Appeal Board (PTAB).
Big Pharma
6 February 2020   US multinational biotechnology company Biogen has successfully defended multiple sclerosis treatment Tecfidera from a patent challenge brought by generic and specialty pharma company Mylan.